ANVS:NYE-Annovis Bio Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 9.09

Change

0.00 (0.00)%

Market Cap

USD 0.12B

Volume

0.14M

Analyst Target

USD 16.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania. Address: 101 Lindenwood Drive, Malvern, PA, United States, 19355

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
BHVN Biohaven Pharmaceutical Holdin..

N/A

USD 5.14B
RCUS Arcus Biosciences Inc

N/A

USD 1.58B
NUVB Nuvation Bio Inc

N/A

USD 0.74B
DNA Ginkgo Bioworks Holdings

N/A

USD 0.50B
ANRO Alto Neuroscience, Inc.

N/A

USD 0.37B
ADCT ADC Therapeutics SA

N/A

USD 0.29B
CYBN Cybin Inc

N/A

USD 0.21B
ARMP Armata Pharmaceuticals Inc

N/A

USD 0.09B
PLX Protalix Biotherapeutics Inc

N/A

USD 0.08B
OSTX OS Therapies Incorporated

N/A

USD 0.07B

ETFs Containing ANVS

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -51.39% 9% A- 9% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return -51.39% 9% A- 10% F
Trailing 12 Months  
Capital Gain 42.70% 48% F 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 42.70% 48% F 84% B
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 151.26% 97% N/A 98% N/A
Dividend Return 151.26% 97% N/A 98% N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 396.74% 9% A- 3% F
Risk Adjusted Return 38.12% 94% A 55% F
Market Capitalization 0.12B 74% C 30% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector